Expression and clinical significance of extracellular matrix protein 1 and vascular endothelial growth factor-C in lymphatic metastasis of human breast cancer

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Wu, Qiu Wan ^a,b   She, Hong Qiang ^b   Liang, Jing ^b   Huang, Yu Fan ^b   Yang, Qing Mo ^b   Yang, Qiao Lu ^b   Zhang, Zhi Ming ^b  

^a FUJIAN MEDICAL UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF XIAMEN UNIVERSITY   (China)

Author keywords

Breast cancer; Extracellular matrix protein 1; Lymphangiogenesis; Vascular endothelial growth factor C

Indexed keywords

ESTROGEN RECEPTOR; MESSENGER RNA; SCLEROPROTEIN; VASCULOTROPIN C; ECM1 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; BREAST EPITHELIUM; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; LYMPH VESSEL; LYMPHANGIOGENESIS; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; AGED; BREAST TUMOR; METABOLISM; MICROVASCULATURE; MIDDLE AGED; PATHOLOGY; VASCULARIZATION;

ADULT; AGED; BREAST NEOPLASMS; EXTRACELLULAR MATRIX PROTEINS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHANGIOGENESIS; LYMPHATIC METASTASIS; LYMPHATIC VESSELS; MICROVESSELS; MIDDLE AGED; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR C;

EID: 84856203237     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-47     Document Type: Article

References (34)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61(2):69-90. 10.3322/caac.20107, 21296855.
2. Ran S, Volk L, Hall K, Flister MJ. Lymphangiogenesis and lymphatic metastasis in breast cancer. Pathophysiology 2010, 17(4):229-251. 10.1016/j.pathophys.2009.11.003, 2891887, 20036110.
3. Achen MG, Stacker SA. Molecular control of lymphatic metastasis. Ann N Y Acad Sci 2008, 1131:225-234. 10.1196/annals.1413.020, 18519975.
4. El-Gohary YM, Metwally G, Saad RS, Robinson MJ, Mesko T, Poppiti RJ. Prognostic significance of intratumoral and peritumoral lymphatic density and blood vessel density in invasive breast carcinomas. Am J Clin Pathol 2008, 129(4):578-586. 10.1309/2HGNJ1GU57JMBJAQ, 18343785.
5. Mathieu E, Meheus L, Raymackers J, Merregaert J. Characterization of the osteogenic stromal cell line MN7: identification of secreted MN7 proteins using two-dimensional polyacrylamide gel electrophoresis, western blotting, and microsequencing. J Bone Miner Res 1994, 9(6):903-913.
6. Uchida T, Hayashi H, Inaoki M, Miyamoto T, Fujimoto W. A failure of mucocutaneous lymphangiogenesis may underlie the clinical features of lipoid proteinosis. Br J Dermatol 2007, 156(1):152-157. 10.1111/j.1365-2133.2006.07583.x, 17199583.
7. Chen H, Jia WD, Li JS, Wang W, Xu GL, Ma JL, Ren WH, Ge YS, Yu JH, Liu WB, et al. Extracellular matrix protein 1, a novel prognostic factor, is associated with metastatic potential of hepatocellular carcinoma. Med Oncol 2011, 28(Suppl 1):318-325.
8. Lal G, Hashimi S, Smith BJ, Lynch CF, Zhang L, Robinson RA, Weigel RJ. Extracellular matrix 1 (ECM1) expression is a novel prognostic marker for poor long-term survival in breast cancer: a Hospital-based Cohort Study in Iowa. Ann Surg Oncol 2009, 16(8):2280-2287. 10.1245/s10434-009-0533-2, 19521735.
9. Kebebew E, Peng M, Reiff E, Duh QY, Clark OH, McMillan A. ECM1 and TMPRSS4 are diagnostic markers of malignant thyroid neoplasms and improve the accuracy of fine needle aspiration biopsy. Ann Surg 2005, 242(3):353-361. discussion 361-363, 1357743, 16135921.
10. Wang L, Yu J, Ni J, Xu XM, Wang J, Ning H, Pei XF, Chen J, Yang S, Underhill CB, et al. Extracellular matrix protein 1 (ECM1) is over-expressed in malignant epithelial tumors. Cancer Lett 2003, 200(1):57-67. 10.1016/S0304-3835(03)00350-1, 14550953.
11. Skobe M, Hawighorst T, Jackson DG, Prevo R, Janes L, Velasco P, Riccardi L, Alitalo K, Claffey K, Detmar M. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med 2001, 7(2):192-198. 10.1038/84643, 11175850.
12. Saharinen P, Tammela T, Karkkainen MJ, Alitalo K. Lymphatic vasculature: development, molecular regulation and role in tumor metastasis and inflammation. Trends Immunol 2004, 25(7):387-395. 10.1016/j.it.2004.05.003, 15207507.
13. Makinen T, Veikkola T, Mustjoki S, Karpanen T, Catimel B, Nice EC, Wise L, Mercer A, Kowalski H, Kerjaschki D, et al. Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGF-C/D receptor VEGFR-3. EMBO J 2001, 20(17):4762-4773. 10.1093/emboj/20.17.4762, 125596, 11532940.
14. Karpanen T, Heckman CA, Keskitalo S, Jeltsch M, Ollila H, Neufeld G, Tamagnone L, Alitalo K. Functional interaction of VEGF-C and VEGF-D with neuropilin receptors. FASEB J 2006, 20(9):1462-1472. 10.1096/fj.05-5646com, 16816121.
15. Karkkainen MJ, Haiko P, Sainio K, Partanen J, Taipale J, Petrova TV, Jeltsch M, Jackson DG, Talikka M, Rauvala H, et al. Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins. Nat Immunol 2004, 5(1):74-80. 10.1038/ni1013, 14634646.
16. Akagi K, Ikeda Y, Miyazaki M, Abe T, Kinoshita J, Maehara Y, Sugimachi K. Vascular endothelial growth factor-C (VEGF-C) expression in human colorectal cancer tissues. Br J Cancer 2000, 83(7):887-891. 10.1054/bjoc.2000.1396, 2374684, 10970690.
17. Su JL, Yang PC, Shih JY, Yang CY, Wei LH, Hsieh CY, Chou CH, Jeng YM, Wang MY, Chang KJ, et al. The VEGF-C/Flt-4 axis promotes invasion and metastasis of cancer cells. Cancer Cell 2006, 9(3):209-223. 10.1016/j.ccr.2006.02.018, 16530705.
18. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 2002, 41(3A):154-161.
19. Van der Auwera I, Cao Y, Tille JC, Pepper MS, Jackson DG, Fox SB, Harris AL, Dirix LY, Vermeulen PB. First international consensus on the methodology of lymphangiogenesis quantification in solid human tumours. Br J Cancer 2006, 95(12):1611-1625. 10.1038/sj.bjc.6603445, 2360768, 17117184.
20. Weidner N. Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors. Breast Cancer Res Treat 1995, 36(2):169-180. 10.1007/BF00666038, 8534865.
21. Schacht V, Dadras SS, Johnson LA, Jackson DG, Hong YK, Detmar M. Up-regulation of the lymphatic marker podoplanin, a mucin-type transmembrane glycoprotein, in human squamous cell carcinomas and germ cell tumors. Am J Pathol 2005, 166(3):913-921. 10.1016/S0002-9440(10)62311-5, 1602360, 15743802.
22. Suzuki H, Onimaru M, Yonemitsu Y, Maehara Y, Nakamura S, Sueishi K. Podoplanin in cancer cells is experimentally able to attenuate prolymphangiogenic and lymphogenous metastatic potentials of lung squamoid cancer cells. Mol Cancer 2010, 9:287. 10.1186/1476-4598-9-287, 2987985, 21034514.
23. Fohn LE, Rodriguez A, Kelley MC, Ye F, Shyr Y, Stricklin G, Robbins JB. D2-40 lymphatic marker for detecting lymphatic invasion in thin to intermediate thickness melanomas: association with sentinel lymph node status and prognostic value-a retrospective case study. J Am Acad Dermatol 2011, 64(2):336-345. 10.1016/j.jaad.2010.03.005, 21238827.
24. Niakosari F, Kahn HJ, Marks A, From L. Detection of lymphatic invasion in primary melanoma with monoclonal antibody D2-40: a new selective immunohistochemical marker of lymphatic endothelium. Arch Dermatol 2005, 141(4):440-444. 10.1001/archderm.141.4.440, 15837861.
25. Rabban JT, Chen YY. D2-40 expression by breast myoepithelium: potential pitfalls in distinguishing intralymphatic carcinoma from in situ carcinoma. Hum Pathol 2008, 39(2):175-183. 10.1016/j.humpath.2007.06.018, 18206495.
26. de Araujo VC, Altemani A, Furuse C, Martins MT, de Araujo NS. Immunoprofile of reactive salivary myoepithelial cells in intraductal areas of carcinoma ex-pleomorphic adenoma. Oral Oncol 2006, 42(10):1011-1016. 10.1016/j.oraloncology.2005.12.021, 16757205.
27. Hasebe T, Yamauchi C, Iwasaki M, Ishii G, Wada N, Imoto S. Grading system for lymph vessel tumor emboli for prediction of the outcome of invasive ductal carcinoma of the breast. Hum Pathol 2008, 39(3):427-436. 10.1016/j.humpath.2007.07.016, 18261627.
28. Cueni LN, Hegyi I, Shin JW, Albinger-Hegyi A, Gruber S, Kunstfeld R, Moch H, Detmar M. Tumor lymphangiogenesis and metastasis to lymph nodes induced by cancer cell expression of podoplanin. Am J Pathol 2010, 177(2):1004-1016. 10.2353/ajpath.2010.090703, 2913355, 20616339.
29. Han Z, Ni J, Smits P, Underhill CB, Xie B, Chen Y, Liu N, Tylzanowski P, Parmelee D, Feng P, et al. Extracellular matrix protein 1 (ECM1) has angiogenic properties and is expressed by breast tumor cells. FASEB J 2001, 15(6):988-994. 10.1096/fj.99-0934com, 11292659.
30. Kinoshita J, Kitamura K, Kabashima A, Saeki H, Tanaka S, Sugimachi K. Clinical significance of vascular endothelial growth factor-C (VEGF-C) in breast cancer. Breast Cancer Res Treat 2001, 66(2):159-164. 10.1023/A:1010692132669, 11437102.
31. Nakamura Y, Yasuoka H, Tsujimoto M, Yang Q, Tsukiyama A, Imabun S, Nakahara M, Nakao K, Nakamura M, Mori I, et al. Clinicopathological significance of vascular endothelial growth factor-C in breast carcinoma with long-term follow-up. Mod Pathol 2003, 16(4):309-314. 10.1097/01.MP.0000062858.98295.9F, 12692195.
32. Zhang XH, Huang DP, Guo GL, Chen GR, Zhang HX, Wan L, Chen SY. Coexpression of VEGF-C and COX-2 and its association with lymphangiogenesis in human breast cancer. BMC Cancer 2008, 8:4. 10.1186/1471-2407-8-4, 2253544, 18190720.
33. Li Z, Zhang Y, Liu Z, Wu X, Zheng Y, Tao Z, Mao K, Wang J, Lin G, Tian L, et al. ECM1 controls T(H)2 cell egress from lymph nodes through re-expression of S1P(1). Nat Immunol 2011, 12(2):178-185. 10.1038/ni.1983, 21217760.
34. McPherson LA, Woodfield GW, Weigel RJ. AP2 transcription factors regulate expression of CRABPII in hormone responsive breast carcinoma. J Surg Res 2007, 138(1):71-78. 10.1016/j.jss.2006.07.002, 17187826.